Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms

Despite the development of targeted therapies, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain the cornerstone of treatment of rheumatoid arthritis (RA). A literature search was conducted on treatment recommendations and relevant papers regarding new insights on thera...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Padjen, Mirna Reihl Crnogaj, Branimir Anić
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	methotrexate rheumatoid arthritis leflunomide disease-modifying antirheumatic drug. Medicine R
Acceso en línea:	https://doaj.org/article/e0bc9db1a4a145ef8336bc1ddecacc68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0bc9db1a4a145ef8336bc1ddecacc68
record_format	dspace
spelling	oai:doaj.org-article:e0bc9db1a4a145ef8336bc1ddecacc682021-12-02T17:46:05ZConventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms0034-62332084-983410.5114/reum.2020.101400https://doaj.org/article/e0bc9db1a4a145ef8336bc1ddecacc682020-12-01T00:00:00Zhttps://www.termedia.pl/Conventional-disease-modifying-agents-in-rheumatoid-arthritis-a-review-of-their-current-use-and-role-in-treatment-algorithms,18,42589,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834Despite the development of targeted therapies, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain the cornerstone of treatment of rheumatoid arthritis (RA). A literature search was conducted on treatment recommendations and relevant papers regarding new insights on therapeutics in rheumatoid arthritis. Methotrexate is considered the “anchor drug” due to its high efficacy as monotherapy and in combination with other conventional and targeted agents. Leflunomide and sulfasalazine are sound alternatives, whereas (hydroxy)chloroquine is primarily used in combination with other csDMARDs. Their use is encouraged in all treatment phases – in combination with targeted agents, and with other csDMARDs. Combining different csDMARDs is especially attractive in lower income settings given the evidence proving (almost) equal efficacy and safety of the csDMARD combination approach compared to the combination of targeted agents with a csDMARD. The aim of this review is to provide a clinically oriented insight into the pharmacology of each csDMARD and their place in treatment algorithms.Ivan PadjenMirna Reihl CrnogajBranimir AnićTermedia Publishing Housearticlemethotrexate rheumatoid arthritis leflunomide disease-modifying antirheumatic drug.MedicineRENRheumatology, Vol 58, Iss 6, Pp 390-400 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	methotrexate rheumatoid arthritis leflunomide disease-modifying antirheumatic drug. Medicine R
spellingShingle	methotrexate rheumatoid arthritis leflunomide disease-modifying antirheumatic drug. Medicine R Ivan Padjen Mirna Reihl Crnogaj Branimir Anić Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
description	Despite the development of targeted therapies, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain the cornerstone of treatment of rheumatoid arthritis (RA). A literature search was conducted on treatment recommendations and relevant papers regarding new insights on therapeutics in rheumatoid arthritis. Methotrexate is considered the “anchor drug” due to its high efficacy as monotherapy and in combination with other conventional and targeted agents. Leflunomide and sulfasalazine are sound alternatives, whereas (hydroxy)chloroquine is primarily used in combination with other csDMARDs. Their use is encouraged in all treatment phases – in combination with targeted agents, and with other csDMARDs. Combining different csDMARDs is especially attractive in lower income settings given the evidence proving (almost) equal efficacy and safety of the csDMARD combination approach compared to the combination of targeted agents with a csDMARD. The aim of this review is to provide a clinically oriented insight into the pharmacology of each csDMARD and their place in treatment algorithms.
format	article
author	Ivan Padjen Mirna Reihl Crnogaj Branimir Anić
author_facet	Ivan Padjen Mirna Reihl Crnogaj Branimir Anić
author_sort	Ivan Padjen
title	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
title_short	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
title_full	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
title_fullStr	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
title_full_unstemmed	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
title_sort	conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/e0bc9db1a4a145ef8336bc1ddecacc68
work_keys_str_mv	AT ivanpadjen conventionaldiseasemodifyingagentsinrheumatoidarthritisareviewoftheircurrentuseandroleintreatmentalgorithms AT mirnareihlcrnogaj conventionaldiseasemodifyingagentsinrheumatoidarthritisareviewoftheircurrentuseandroleintreatmentalgorithms AT branimiranic conventionaldiseasemodifyingagentsinrheumatoidarthritisareviewoftheircurrentuseandroleintreatmentalgorithms
_version_	1718379561202221056

Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms

Ejemplares similares